Every material Form 8-K Surrozen, Inc./DE has filed with the SEC since August 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Surrozen completed the second and final tranche of its March 2025 private placement on October 20, 2026, raising approximately $95.1 million in gross proceeds before placement agent fees and other expenses. The company says the proceeds extend its expected cash runway into 2029, but the issuance adds shares, pre-funded warrants and warrants that dilute existing shareholders.
Issued 5,741,605 common shares at $11.60 per share, plus pre-funded warrants for 2,456,500 shares and Series E warrants for 4,099,052 shares with an exercise price of $11.54
Closing was triggered by FDA clearance of the Investigational New Drug application for SZN-8141 announced October 2, 2026
Company expects cash runway into 2029, including funding for the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143
Company agreed to file a resale registration statement within 30 calendar days of the closing
Surrozen said the FDA cleared its Investigational New Drug application for SZN-8141, a treatment for diabetic macular edema, allowing clinical development to advance. The clearance satisfies a milestone for the second closing of its March 2025 private placement, which is expected to bring about $95.1 million in gross proceeds on or about October 20, 2026, before placement agent fees and other expenses.
FDA clearance of the SZN-8141 IND took effect after the statutory 30-day review period, announced October 2, 2026
First patient dosing in the Phase 1b/2a DUET study is expected in Q4 2026, with initial data expected in 2H 2027
Second closing of the March 2025 two-tranche private placement expected on or about October 20, 2026, with approximately $95.1 million in gross proceeds
Surrozen must file a Form S-3 resale registration statement within 30 calendar days after the closing
Surrozen reported second quarter 2026 revenue of $5.0 million, up from $983,000 a year earlier, from a Boehringer Ingelheim milestone. Net income rose to $50.2 million, but the company said it was driven by $59.6 million in non-cash gains on fair value changes, while its operating loss widened to $10.4 million. Diluted earnings per share were $(0.41), compared with $2.55 a year earlier, and cash fell to $102.0 million from $106.9 million at March 31, 2026.
Q2 2026 collaboration and license revenue was $5.0 million from a June 2026 Boehringer Ingelheim milestone; prior-year research service revenue was $983,000.
Loss from operations was $10.4 million versus $9.0 million a year earlier, as R&D rose to $8.5 million and G&A to $6.9 million.
Diluted EPS was $(0.41) versus $2.55 a year earlier, while the six-month net loss was $77.3 million compared with net income of $12.8 million in the prior-year period.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Surrozen, Inc./DE filing is on SEC EDGAR ↗. 8-K briefs of other companies →